Published: 2016-12-16

Association of galectin-3 with high cardiovascular risk in patients with type 2 diabetes attending a multi-specialty hospital in South India

Damal Kandadai Sriram, Govindaraj Gowri, Sujithera Haridoss, Surendran Venkatesan, Ilayaraja Rajendran, Melvin George


Background: Diabetes mellitus is a chronic hyperglycemic condition that continues to be associated with high mortality and morbidity. Galectin-3 is a β-galactoside binding lectin and is a potential marker for inflammation, immunity and fibrosis. The aim of the study was to evaluate the relationship between Galectin-3 and baseline characteristics and to find the association between Galectin-3 and high cardiovascular risk in a group of Type-2 diabetes patients.

Methods: A total of 100 patients with type-2 diabetes mellitus were included in the study after obtaining informed consent. The study participants were divided into two groups; those with diabetes for duration of less than 5 years as Group-1 and diabetes greater than 5 years as Group-2. Patients were also divided into three tertiles based on the Inter heart risk score (IHR). Five ml of blood was withdrawn from the ante-cubital vein and the serum obtained was subjected to analysis for estimating concentration of Galectin-3.

Results: There was no significant difference between the Group-1 and Group-2 except gender variation with a significantly higher preponderance of males in Group 2. There was a significant correlation between Galectin-3 and parameters such as systolic blood pressure (r=0.033, p=0.03), creatinine (r=0.20, p=0.03), IHR (r=0.69, p=0.0001). Patients in the high risk category had greater levels of Galectin-3 compared to those with low and intermediate IHR.

Conclusions: Galectin-3 concentration is elevated in diabetes patients and correlates with the IHR-Score. Thus Galectin-3 could be a useful biomarker for prediction of cardiovascular risk in diabetic subjects.


Cardiovascular risk, Diabetes, Galectin-3, Heart disease, Interheart risk score

Full Text:



Takian A, Kazempour-Ardebili S. Diabetes Dictating Policy: An Editorial Commemorating World Health Day. Int J Health Policy Manag. 2016;5:571-3.

Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance in India. Diabetes Atlas. Gan D Ed. International Diabetes Federation, Belgium. 2006;15-103.

Zargar AH, Wani AI, Masoodi SR, Laway BI, Bashir MI. Mortality in diabetes mellitus-data from a developing region of the world. Diabetes Res Clin Pract. 1999;43:67-74.

Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander? Am J Nephrol. 2016;43:305-17.

Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, et al.Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and Biochemistry. 1994;33:14109-14.

Dumic J, Dabelic S, Flogel M. Galectin-3:an open-ended story. Biochim Biophys Acta. 2006;1760:616-35.

Fortuna-Costa A, Gomes AM, Kozlowski EO, Stelling MP, Pavao MSG. Extracellular Galectin-3 in Tumor Progression and Metastasis. Front Oncol. 2014;4:138.

Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230:160-71.

Seferovic JP, Lalic NM, Floridi F, Testic M, Sefrovic PM, Giga V, et al. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. Clin Chem Lab Med. 2014;52:1499-505.

Ohkura T, Fujioka Y, Nakanishi R, Shiochi H, Sumi K, Yamamoto N, et al. Low serum galectin-3 concentrations are associated with insulin resistance in patients with type 2 diabetes mellitus. Diabetol & Metab Syndr. 2014;6(1):106.

Yilmaz H, Cakmak M, Inan O, Darcin T, Akcay A. Increased levels of galectin-3 was associated with pre diabetes and diabetes: new risk factor? J Endocrinol Invest. 2014;38:527-33.

Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, et al. serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab. 2010;95:1404-11.

Van Der Velde AR, Meijers WC, Ho JE, Brouwers FP, Rienstra M, Bakker SJ ,et al. serial galectin-3 and future cardiovascular disease in the general population. Heart. 2016;102:1134-41.

Nayor M, Wang N, Larson MG, Vasan RS, Levy D, Ho JE, et al. Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community. J Am Heart Assoc. 2015;5(1). pii: e002347.

Ozturk D, Celik O, Satilmis S, Aslan S, Erturk M, Cakmak HA, et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron artery Dis. 2015;26:396-401.

Yücel N, Cakir Madenci O, Boluk A, Koroglu Daqdelen L, Temel Y, Sargin M, et al. Is galectin-3 associated with urinary albumin excretion in type2 diabetes? Endokrynol Pol 2016.

de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population, J Intern Med. 2012;272:55-64.

Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67-75.

O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;249:1470-7.

Drechsler C, Delgado G, Wanner C, Blouin K, Pilz S, Tomaschitz A, et al. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J Am Soc Nephrol. 2015;26:2213-21.